Trials / Completed
CompletedNCT00477334
Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients
A Randomized, Multicenter, Double-blind Study to Compare the Efficacy of Single-day Treatment (1000 mg b.i.d.) With Famciclovir Compared to That of Placebo in Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Immunocompetent Black Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 463 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of single-day famciclovir episodic treatment in Black patients with recurrent genital herpes
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Famciclovir | oral; two 500 mg tablets twice a day; single day treatment |
| DRUG | Placebo | oral; two tablets twice a day; single day treatment |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2007-05-23
- Last updated
- 2011-03-28
- Results posted
- 2011-03-16
Locations
43 sites across 2 countries: United States, South Africa
Source: ClinicalTrials.gov record NCT00477334. Inclusion in this directory is not an endorsement.